Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

NCT01618695 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT01618695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01618695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures
Lead sponsor
Eisai Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 15, 2012
Completion date
May 28, 2020
Enrollment
940 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

partial-onset seizures